|
Our medical staff is committed to offering the most up-to-date
treatments available. Most of these will be available at Saint
Barnabas Medical Center, although there may be times we recommend
that you consider a very specialized treatment which may be available
only at another center. In addition, to broaden your treatment
options, we will inform you of any clinical trials for which you
may be eligible. Our Center is involved in many clinical trials
run both by the National Cancer Institute and by individual pharmaceutical
companies. Today's clinical trials lead to tomorrow's breakthrough
treatments.
|
CALGB80101 |
Phase III Intergroup Trial
of Adjuvant Chemoradiation After Resection of Gastric or
Gastroesophageal Adenocarcinoma |
CTSU E5202 |
A Randomized Phase III Study
Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU,
Leucovorin, Oxaliplatin and Bevacizumab in Patients with
Stage II Colon Cancer at High Risk for Recurrence to Determine
Prospectively the Prognostic Value of Molecular Markers |
CTSU N0147
|
A Randomized Phase III Trial
of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin
(CF) with or without Cetuximab (C225) after Curative Resection
for Patients with Stage III Colon Cancer |
RAD001-CRAD001C2324 |
A randomized double-blind phase
III study of RAD001 10 mg/d plus best supportive care versus
placebo plus best supportive care in the treatment of patients
with advanced pancreatic neuroendocrine tumor (NET) |
| [ top ] |
|
NSABP C-10 |
A Phase II Trial of mFOLFOX6
Chemotherapy Plus Bevacizumab for Patients with Unresectable
Stage IV Colon Cancer and a Synchronous Asymptomatic Primary
Tumor |
S0600 |
SUSPENDED - Phase III Trial of Irinotecan-Based
Chemotherapy Plus Cetuximab with or without Bevacizumab
as Second-Line Therapy for Patients with Metastatic Colorectal
Cancer who have Progressed on (1st line) Bevacizumab with
either FOLFOX, OPTIMOX or XELOX |
| |
[ top ] |
|
|
